Effect of ligand of peroxisome proliferator-activated receptor γ on the biological characters of hepatic stellate cells

Yan-Tong Guo, Xi-Sheng Leng, Tao Li, Ji-Run Peng, Sheng-Han Song, Liang-Fa Xiong, Zhi-Zhong Qin

Abstract

AIM: To study the effect of rosiglitazone, which is a ligand of peroxisome proliferator-activated receptor gamma (PPARγ), on the expression of PPARγ in hepatic stellate cells (HSCs) and on the biological characteristics of HSCs.

METHODS: The activated HSCs were divided into three groups: control group, 3 μmol/L rosiglitazone group, and 10 μmol/L rosiglitazone group. The expression of PPARγ, α-smooth muscle actin (α-SMA), and type I and III collagen was detected by RT-PCR, Western blot and immunocytochemical staining, respectively. Cell proliferation was determined with methylthiazolyltetrazolium (MTT) colorimetric assay. Cell apoptosis was demonstrated with flow cytometry.

RESULTS: The expression of PPARγ at mRNA and protein level markedly increased in HSCs of 10 μmol/L rosiglitazone group (t value was 10.870 and 4.627 respectively, P<0.01 in both). The proliferation of HSCs in 10 μmol/L rosiglitazone group decreased significantly (t = 5.542, P<0.01), α-SMA expression level and type I collagen synthesis ability were also reduced versus controls (t value = 10.256 and 14.627 respectively, P<0.01 in both). The apoptotic rate of HSCs significantly increased in 10 μmol/L rosiglitazone group versus control (χ² = 16.682, P<0.01).

CONCLUSION: By increasing expression of PPARγ in activated HSCs, rosiglitazone, an agonist of PPARγ, decreases α-SMA expression and type I collagen synthesis, inhibits cell proliferation, and induces cell apoptosis.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Peroxisome proliferator-activated receptor gamma; Hepatic stellate cell; Rosiglitazone

Guo YT, Leng XS, Li T, Peng JR, Song SH, Xiong LF, Qin ZZ. Effect of ligand of peroxisome proliferator-activated receptor γ on the biological characters of hepatic stellate cells. World J Gastroenterol 2005;11(30):4735-4739 http://www.wjgnet.com/1007-9327/11/4735.asp

INTRODUCTION

It is well established that hepatic fibrosis is the pathological basis on which chronic liver diseases further progress to hepatic cirrhosis[1]. Multiple factors produce hepatic lesions, contributing to hepatic fibrosis[2]. Studies show that reversing hepatic fibrosis may block the progression of hepatic cirrhosis[3]. Hepatic stellate cell (HSC) is now well established as the key cellular element involved in the development of hepatic fibrosis[4]. When the liver is attacked by pathogenic factors, HSCs, a pericyte-like mesenchymal liver cell population, transform from a “quiescent” status (“resting” HSC) into myofibroblast-like cells (“activated” HSC) with the latter synthesizing and secreting extracellular matrix (ECM), tissue inhibitor of matrix metalloproteinases and multiple cytokines, which contribute to collagen deposition, leading to fibrosis[5-7]. Recently, it has been reported that resting HSC expresses peroxisome proliferator-activated receptor gamma (PPARγ); the expression of PPARγ gradually decreases during the course of activation of HSC cultured in vitro, indicating that certain expression level of PPARγ may be a crucial element that inhibits the natural activation of HSC[8-14]. The present study was designed to investigate whether activated HSCs (myofibroblast-like cells) treated by PPARγ-specific ligands were able to enhance the expression of PPARγ and its effect on HSC proliferation, collagen secretion, and cell apoptosis.

MATERIALS AND METHODS

HSCs of rats

HSCs of rats were obtained from HSC strain rHSC-99 produced by the Department of Hepatobiliary Surgery, Peking University People’s Hospital and this strain had the characteristics of activated HSCs[15].

Rosiglitazone

A high-affinity specific ligand of PPARγ, was purchased from GlaxoSmithKline Investment Co., Ltd.

Experimental groups

Three groups were set up in the study, blank control group, 3 μmol/L rosiglitazone, and 10 μmol/L rosiglitazone groups, respectively.
Semi-quantitative RT-PCR detection of PPARγ

The extraction and reverse transcription of RNA were performed according to the directions of the kits (Taq PCR MasterMix, TW-Biotech Co., Ltd.; PPARγ primer was synthesized by Shanghai Bioengineering Co., Ltd, with an upstream fragment of CCTTGGAAGACATTGTAT, a downstream fragment of ACTGGCACCCCTGAAAAATG and an extension fragment of 222 bp. The internal reference β-actin was designed with an upstream fragment of TGGGACGATATGGAAGAGAT, a downstream fragment of ATTTGCCGATAGTGACCT and an extension fragment of 522 bp. PCR reaction is as follows. PPARγ primers were added to reaction systems, which conditions were set at 95 °C for 5 min; 94 °C for 20 s, 55 °C for 30 s, 72 °C for 40 s, totally 29 cycles; finally at 72 °C for 5 min. The products of PCR were photographed after electrophoresis on 2% agarose gel and the gray scale values determined through image analysis. The sample quantities were adjusted to make the gray scale value in each β-actin group stay at a relatively identical level and then the gray scale values of PPARγ between groups were compared.

Detection of PPARβ protein by western blot

In each electrophoresis lane, a sample of 30 µg protein was added and after polyacrylamide gel electrophoresis at a volume fraction of 30%, the electrophoretic proteins were transferred onto nitrocellulose membranes, blocked with 5% fat-free milk in TBST buffer (20 mmol/L Tris-HCl, 137 mmol/L NaCl, and 0.05% Tween 20). The membranes were incubated with the first and second antibody, respectively. Antigen-antibody complexes were visualized using the enhanced chemiluminescence detection system according to the manufacturer’s instructions (Santa Cruz Biotechnology, Inc.). Membranes were exposed to autoradiography, and signals were scanned for quantitation. Image analysis was done on the strips to determine the gray scale value. The expression quantity of PPARγ by HSC in each group was expressed relative to that of the control group.

Detection of PPARγ protein by immunocytochemistry method

After HSCs were cultured on the slides, they were fixed in neutralized 40% formaldehyde, then detected with SP method (Santa Cruz Biotechnology, Inc.) and examined under a microscope. Those cells whose nuclei were brown were defined as positive.

Effect of rosiglitazone on HSCs proliferation

Cells were incubated in a 96-well plate. The cells grew in DMEM culture medium containing a volume fraction of 16% calf serum until the logarithmic growth phase, and were then incubated for 24 h in DMEM culture medium that contained a volume fraction of 1% calf serum, which could stop the growth of cells. After that, cells were incubated in culture media respectively containing a volume fraction of 16% calf serum, as blank control group, and rosiglitazone groups of a final concentration of 3 and 10 µmol/L. And the absorbance value of A570 was read on the microplate reader for each well using MTT colorimetric assay at 0, 24, and 48 h.

Effect of rosiglitazone on the synthesis of α-SMA of HSCs and collagen I and III

HSCs from control group, 3 µmol/L rosiglitazone group and 10 µmol/L rosiglitazone group were detected by Western blot and immunocytochemistry respectively.

Effect of rosiglitazone on HSCs apoptosis

The apoptotic index was determined by flow cytometry (Applied Biosystems). A total of 1×10⁵/mL cells in a suspension were fixed with precooled 70% ethanol solution and stained, and analyzed by a flow cytometer and the apoptotic index was determined by Multicycles software.

Statistical analysis

t-Test and χ² test were employed to analyze all the data concerned. P<0.05 was taken as significant.

RESULTS

10 µmol/L rosiglitazone enhanced the expression of HSC PPARγ mRNA

At 3 µmol/L of rosiglitazone, no significant difference was seen in the expression of PPARγ mRNA in HSCs compared with the control group. There was a significant increase in the expression of PPARγ mRNA in HSCs by 10 µmol/L rosiglitazone compared with the control group (t = 10.87, P<0.01, Figure 1). Meanwhile obvious expression of all β-actin was observed.

Western blot demonstrated that the expression of PPARγ protein increased by 10 µmol/L rosiglitazone

At 3 µmol/L rosiglitazone, no significant difference was seen in the expression of PPARγ protein in HSCs compared with control group. The expression of PPARγ protein in HSCs by 10 µmol/L rosiglitazone was significantly increased compared with that of the control group (t = 4.627, P<0.01, Figure 2).

Immunocytochemistry demonstrated enhanced expression of PPARγ protein in HSCs in 10 µmol/L rosiglitazone group

In the blank control group and 3 µmol/L rosiglitazone groups of a final concentration of 3 and 10 µmol/L rosiglitazone...
group, no evident expression of PPARγ protein was found by immunocytochemistry. In the 10 µmol/L rosiglitazone group, there was a relatively increased expression of PPARγ protein in the nucleus of most HSCs and in the cytoplasm of some HSCs (Figure 3A). The expression of PPARγ protein seen in the cytoplasm in some of the HSCs might be proteins not entering into the cell nucleus, and the precursor of PPARγ proteins in cytoplasm.

10 µmol/L rosiglitazone markedly inhibited HSCs proliferation

There was no significant difference in the proliferation activity of HSCs between 3 µmol/L rosiglitazone group and the control group. After a 24 and 48 h culture period, the proliferation activity of 10 µmol/L rosiglitazone group was lower than that in both the control group (t value = 5.542 and 19.293, respectively, P<0.01 in both) and the 3 µmol/L rosiglitazone group (t value = 6.880 and 10.502 respectively, P<0.01 in both, Table 1).

**Table 1** Effect of rosiglitazone on proliferation of rHSC-99

| Groups     | 0 h       | 24 h       | 48 h       |
|------------|-----------|------------|------------|
| Controls   | 0.21±0.041| 0.62±0.088 | 1.00±0.045 |
| 3 µmol/L   | 0.22±0.038| 0.63±0.060 | 0.93±0.049 |
| 10 µmol/L  | 0.22±0.064| 0.33±0.085b| 0.49±0.060b|

*P<0.01 vs controls or 3 µmol/L treatment group.

10 µmol/L rosiglitazone decreased synthesis of α-SMA, collagen I in HSCs

Detection of synthesis of α-SMA, collagen I and III in HSCs by immunocytochemistry indicated that cytoplasmic staining of α-SMA and collagen I and III in both the blank control group and 3 µmol/L rosiglitazone group was strongly positive. In 10 µmol/L rosiglitazone group, the expression of α-SMA and collagen I decreased significantly while there was no distinct change in the expression of collagen III. Through gray-scale scanning analysis, the quantity of α-SMA and collagen I decreased 48% and 42%, respectively compared with the blank control group (t value = 10.256 and 14.627, respectively, P<0.01 in both). Western blot detection of α-SMA showed that there was no significant difference between 3 µmol/L rosiglitazone group and blank control group. The gray-scale value of α-SMA strap of 10 µmol/L rosiglitazone group significantly decreased compared with the blank control group (t = 4.627, P<0.01).

10 µmol/L rosiglitazone accelerated HSC apoptosis

Flow cytometry analysis revealed that HSC apoptosis index in 10 µmol/L rosiglitazone group was 23.8%, significantly higher than that in the control group (3.6%, χ² = 16.682, P<0.01).

**DISCUSSION**

Excessive production and deposition of extracellular matrix is one of the main characteristics of hepatic fibrosis, in which type I collagen is an essential component[16]. Type I collagen mainly comes from activated myofibroblast HSC[17]. At present, studies on hepatic fibrosis are increasingly concentrating on HSC, in order to find specific and efficient approaches to inhibit and reverse hepatic fibrosis[1,2,18,19]. Several studies demonstrated that resting HSCs express PPARγ and when resting HSCs are activated to become myofibroblast HSCs, they lose the ability to transcribe and express PPARγ[8,9,12,20,21]. PPARγ is a member of nuclear receptor superfamily[22]. When combined with its ligand, PPARγ forms heterodimer with retinoid X receptor, which is then combined with peroxisome proliferator response element (PPRE) at the upstream of regulated gene promoter to play a role in transcription and regulation[23]. Rosiglitazone is widely used in clinical practice as an insulin sensitizer, and at present, it is identified as a high-affinity specific ligand of PPARγ, which can promote the expression of PPARγ in cells and enhance the transcription activity of PPARγ[24-26]. According to the change of blood drug level after rosiglitazone is taken, 2-3 µmol/L rosiglitazone is believed...
to be at a relatively high level, but in a preliminary experiment, only 10 μmol/L rosiglitazone displayed a notable effect. Therefore, we set up a blank control group, 3 μmol/L rosiglitazone group, and 10 μmol/L rosiglitazone group. It was shown that 10 μmol/L rosiglitazone remarkably increased the transcription activity and expression level of PPARγ in HSC, indicating that using PPARγ-specific ligand was able to recover the expression and transcription activity of PPARγ to a certain extent.

HSC strain rHSC-99 has been established by serial passage of rat HSC. This strain has the characteristics of activated myofibroblast HSC and highly expresses α-SMA and collagen I and III[19]. The results of our experiment demonstrate that while 10 μmol/L rosiglitazone remarkably postponed or reversed hepatic fibrosis has been considered as an efficient countermeasure to collagen degradation through decreasing activated HSCs, but also weakening the inhibitory effect on activated HSC, thus not only reducing the synthesis of collagen, but also the tumor necrosis factor AP-1, STAT, and NF-κB. It is assumed that, there may be similar mechanism in HSC, indicating that using PPARγ enhances the transcription activity and expression level of PPARγ and collagen I and the proliferation of HSCs.

At present, the mechanism that enhances the transcription activity and expression level of PPARγ in HSC can inhibit the expression of α-SMA and collagen I and II[18]. PPARγ has a regulatory effect on multiple genes, but little research has been done regarding the effect of changes in PPARγ expression and transcription activity on related genes of HSC[9,12,13,21,29]. Researches have shown that the enhancement of PPARγ transcription activity can inhibit the expression of TGF-β1 mRNA induced by TGF-β, suggesting that the activation of PPARγ might block the autocrine loop of TGF-β1 and further reduce TGF-β1-induced secretion of collagen and HSCs proliferation[10-12]. In researches on human and mouse macrophages[13-16], it was found that there existed an interaction between PPARγ and AP-1 signal pathway and the activation of PPARγ could inhibit the activity of transcription factor AP-1, STAT, and NF-kB. It is assumed that, there may be similar mechanism in HSC that PPARγ through inhibiting the activation of transcription factor AP-1, STAT, and NF-kB, further plays an inhibitory role in HSC proliferation and expression of collagen.

HSC apoptosis can reduce the absolute quantity of activated HSC, thus not only reducing the synthesis of collagen, but also weakening the inhibitory effect on collagen degradation through decreasing activated HSCs to reduce the expression of matrix tissue inhibitor of metalloproteinases[17]. Therefore, induction of HSC apoptosis has been considered as an efficient countermeasure to postpone or reverse hepatic fibrosis[18]. Rosiglitazone, as a specific ligand of PPARγ, can significantly increase HSC apoptosis rate.

The results of our experiment indicate that PPARγ-specific ligand rosiglitazone, through activating the expression of PPARγ, can inhibit the expression of α-SMA and collagen I in activated HSCs, the proliferation of activated HSCs and induce apoptosis of activated HSCs.

REFERENCES

1 Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-1835
2 Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29: 836-847
3 Brenner DA. Signal transduction during liver regeneration. J Gastroenterol Hepatol 1998; 13(Suppl): S93-95
4 Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to injury. J Biol Chem 2000; 275: 2247-2250
5 Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, Tsukamoto H. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004; 279: 4820-4828
6 Eng FJ, Friedman SL, Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279: G7-G11
7 Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, Schuppan D, Rotella CM, Surrenti C. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology 1993; 105: 245-253
8 Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424
9 Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998; 18: 2-13
10 Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003; 285: G20-30
11 Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-35722
12 Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004; 279: 11392-11401
13 Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002; 50: 891-896
14 Marra F, Elesen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478
15 Leng XS, Weng SG, Li T, Wei YH, Peng JR, Du RY. Establishment of a new rat hepatic stellate cell line rHSC-99 with characteristics of myofibroblast cell. ACTA ANATOMICA SINICA 2003; 34: 269-274
16 Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-719
17 Milani S, Herbst H, Schuppah D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology 1989; 10: 84-92
18 Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-1940
19 Solis-Herruzo JA, de la Torre P, Munoz-Yague MT. Hepatic stellate cells (HSC): architects of hepatic fibrosis. Rev Esp Enferm Dig 2003; 95: 436-439
20 Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000; 20: 191-199
21 Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, Casini A. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 2000; 31: 101-108
22 Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53(Suppl 1): S43-50
23 Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator-activated receptor gamma. **Curr Opin Genet Dev** 1995; 5: 571-576

24 Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. **Diabetes** 1996; 45: 1661-1669

25 Greene DA. Rosiglitazone: a new therapy for Type 2 diabetes. **Expert Opin Investig Drugs** 1999; 8: 1709-1719

26 Miller JL. Rosiglitazone approved for treatment of type 2 diabetes. **Am J Health Syst Pharm** 1999; 56: 1292-1294

27 Balfour JA, Plosker GL. Rosiglitazone. **Drugs** 1999; 57: 921-932

28 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). **J Biol Chem** 1995; 270: 12953-12956

29 Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. **Biochem Biophys Res Commun** 2004; 315: 187-195

30 Sung CK, She H, Xiong S, Tsukamoto H. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. **Am J Physiol Gastrointest Liver Physiol** 2004; 286: G722-729

31 Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. **Biochem Biophys Res Commun** 2002; 291: 55-61

32 Parkes JG, Templeton DM. Effects of retinol and hepatocyte-conditioned medium on cultured rat hepatic stellate cells. **Ann Clin Lab Sci** 2003; 33: 295-305

33 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. **Nature** 1998; 391: 82-86

34 Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. **Nature** 1998; 391: 79-82

35 Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: Possible relevance to human fibrotic disorders. **Proc Natl Acad Sci USA** 2002; 99: 15072-15077

36 Marra F. Hepatic stellate cells and the regulation of liver inflammation. **J Hepatol** 1999; 31: 1120-1130

**Science Editor** Zhu LH  **Language Editor** Elsevier HK